【摘要】 急性髓系白血病(Acute myeloid leukemia,AML)是一类高度异质性疾病,过去常规诱导化疗和各类支持治疗为主,但随着二代测序等技术应用以来,AML药物迅速发展。本文从细胞毒药物、小分子靶向药物以及免疫靶向药物等方面,系统概述AML的致病机制,以及临床研究中较为前沿的各类新型药物(如FLT3抑制剂Midostaurin、IDH抑制剂AG-221和CPX-351等)的研究进展,旨在为AML的新药研发提供参考。更多还原

【Abstract】 Acute myeloid leukemia(AML) is a highly heterogeneous disease.Previously,AML treatment has been dominated by conventional induction chemotherapy and various supportive treatments,while new drug treatments for AML have been developed fast since the application of technologies such as second-generation sequencing.This article systematically summarizes the pathogenic mechanism of AML from the point of view of cytotoxic drugs,small molecule targeted drugs and immunotargeted drugs,and as well summarizes novel drugs that are more advanced in clinical research(such as the FLT3 inhibitor midostaurin,IDH inhibitors AG-221,and CPX-351),aiming to provide reference for the development of new drugs for AML.更多还原